Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European Delphi panel

Table 4 Proportion of patients with NDM requiring mental health support in the UK

Mental health resource	BSC – Mean % of patients requiring resource (range)	Mexiletine – Mean % of patients requiring resource (range)	Difference (%)	BSC:mexiletine ratio^a
Neuropsychologist	0 (0)	0 (0)	0	1
General practitioner (mental health-related visits)	42.5 (0-100)	37.5 (0-100)	-5	1.1
Psychiatrist	2.5 (0-10)	2.5 (0-10)	0	1
Psychologist	3.75 (0-10)	3.75 (0-10)	0	1

Four experts completed this question in RD2, one expert dropped-out
Key: BSC Best supportive care (defined as any supportive care that symptomatic adult patients with NDM may receive that does not involve symptom-modifying pharmacological treatment; includes, for example, the use of supportive medication [e.g. pain killers], mobility aids, physiotherapy or speech therapy), HRU Healthcare resource utilization
^aThe ratio was calculated by dividing the mean proportion of patients receiving BSC that require a resource by the mean proportion of patients treated with mexiletine (NaMuscla) that require the resource

ISSN: 1471-2377